Protara Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference
September 06 2022 - 8:00AM
Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage
company developing transformative therapies for the treatment of
cancer and rare diseases, today announced that management will
present at the H.C. Wainwright 24th Annual Global Investment
Conference being held September 12 through September 14, 2022.
The prerecorded presentation will become
available on-demand on Monday, September 12, 2022 at 7:00 a.m. ET
and can be accessed by visiting the Events and Presentations
section of the Company’s website: https://ir.protaratx.com. The
webcast will be archived for 90 days following the
presentation.
About Protara
Therapeutics, Inc.
Protara is committed to identifying and
advancing transformative therapies for people with cancer and rare
diseases. Protara’s portfolio includes its lead program, TARA-002,
an investigational cell-based therapy being developed for the
treatment of non-muscle invasive bladder cancer and lymphatic
malformations, and IV Choline Chloride, an investigational
phospholipid substrate replacement therapy for the treatment of
intestinal failure-associated liver disease. For more information,
visit www.protaratx.com.
Company Contact:
Justine O'MalleyProtara
TherapeuticsJustine.OMalley@protaratx.com646-817-2836
Protara Therapeutics (NASDAQ:TARA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Protara Therapeutics (NASDAQ:TARA)
Historical Stock Chart
From Jul 2023 to Jul 2024